July 09, 2024
1 min watch
Save
VIDEO: Gene therapy candidate may reduce treatment burden in neovascular AMD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Adam Turpcu, PhD, of Adverum Biotechnologies discusses Ixo-vec for neovascular age-related macular degeneration.
The gene therapy candidate Ixo-vec (ixoberogene soroparvovec) has shown promise in reducing the number of aflibercept injections, “and we think that can be really beneficial to patients in the real world who suffer from increased treatment burden in this disease area,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Turpcu reports being the vice president of clinical development and access strategy at Adverum.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.